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Abstract
The forthcoming implementation of the European Clinical Trial Regulation (Regula-
tion (EU) No. 536/2014), which is expected to facilitate the conduct of clinical trials 
across the European Union, will require National Authorities to create the best condi-
tions for the implementation of the new Regulation through national guidelines, so that 
sponsors may reconsider Europe as a prime location for planning clinical trials. During 
a meeting titled “Innovation in Clinical Research”, an expert panel discussed potential 
local advances fostering competitiveness of European clinical research with representa-
tives of the pharmaceutical industry, patient organisations and Italian regulatory agency 
in view of the forthcoming implementation of (EU) No. 536/2014 on clinical trials of 
medicinal products. In this article we summarise the findings of the meeting, describe 
features characterising clinical research patterns and offer some suggestions on the pos-
sible involvement of all stakeholders in order to foster research innovation and allow the 
timely access to novel medicines for patients.
BACKGROUND
Between 2007 and 2012, overall global biomedical 
research and development (R&D) expenditures in-
creased by 18.4%, while remaining static or decreasing 
in North America and Europe [1]. In parallel, between 
2004 and 2016, the number of human studies con-
ducted globally increased from 12 018 to 234 321 [2], 
while the share of clinical trials (CTs) performed in the 
European Union (EU), including Italy, decreased by 
15% between 2009 and 2015 [3, 4]. These trends have 
increased demands for regulatory harmonization and 
improved efficiency of CT research [5]. Cost, speed 
of approval and shortcomings of the European Clini-
cal Trial Directive [6] are cited in explanation of the 
declining clinical trial numbers. Dominant factors in 
trial site selection are investigator-dependent factors 
and ease of approval. Therefore, fostering competitive-
ness and bringing more clinical trials to Europe may 
depend more on harmonization of approval processes, 
cultivating centers of excellence and reducing “hid-
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den” indirect costs rather than additional government 
investment [7].
An expert panel of investigators with strong expertise 
in clinical research, together with members of the phar-
maceutical industry, patient organizations and the Ital-
ian regulatory agency met under the banner of “Innova-
tion in Clinical Research” to identify ways to involve 
all stakeholders in advancing Italian and European 
competitiveness in the global “trial market” to foster re-
search innovation and timely access to novel medicines 
alongside the implementation of the Regulation (EU) 
No. 536/2014 on CTs for medicinal products [8].
 
THE EUROPEAN REGULATORY 
FRAMEWORK: PRESENT AND FUTURE
Europe has consistently expressed the desire to 
maintain and improve its competitiveness as an attrac-
tive place for conducting CTs. Directive 2001/20/EC 
[6], envisioned to support this goal, has failed, in part 
because of differences in implementation levels across 
member states (MSs), excessive bureaucracy, the need 
for multiple applications, difficulties in handling diver-
gent regulatory decisions and lengthy/uncertain time 
intervals for authorisations [7, 9].
CTs require the involvement of many/all EU MSs to 
recruit sufficient patients; new efficient and rapid pro-
cedures for CT authorisation are needed. A key innova-
tion of Regulation 536/2014 [8] was a single electronic 
application for all interventional studies, to be submit-
ted via a EU submission portal once it becomes fully 
functional.
Regulatory policy makers of all EU MSs should work 
to create local harmonized conditions and improve 
local standards of clinical research at all levels, allow-
ing effective implementation of the new Regulation 
through pilot schemes such as the Voluntary Harmoni-
zation Procedure. 
PREPARING FOR CHANGE: THE ITALIAN 
CASE STUDY
The Italian situation is similar to that of several other 
European MSs. CTs are currently regulated by Leg-
islative Decree no. 211 [10], implementing Directive 
2001/20/EC [6]; the Italian Medicines Agency (Agenzia 
Italiana del Farmaco, AIFA) is the Competent Authority 
for issuing authorization of all medicinal CTs from Phase 
I-IV, although AIFA collaborates with the Italian Nation-
al Institute of Health (Istituto Superiore di Sanità) for 
the evaluation of phase I and I/II studies.
Electronic submission of data and supporting docu-
ments are submitted through AIFA’s portal, the Nation-
al Monitoring Centre on Clinical Trials of Drugs (Os-
servatorio nazionale sulla Sperimentazione Clinica dei 
medicinali). Many challenges face the Italian Regula-
tory Authorities and Ethics Committees (ECs) in fully 
complying with the new Regulations: strict time frames 
for assessments, need for internal consistency for opin-
ions, difficulties in identifying experts in specific areas, 
and adequate internal resources. 
Reorganization of the operations of ECs to reduce 
their excessive numbers and simplify the complex regu-
latory framework while boosting operating standards 
and training is needed, with the goal of a few regional/
national ECs. 
“Hidden” costs related to bureaucracy, slow recruit-
ment or poor overall site performance relative are per-
ceived to be factors influencing the selection of Italy 
as a site for CTs [7]; carefully crafted harmonization 
of approvals, greater visibility of centers of excellence 
and reduction in “hidden” costs are needed to reach the 
goals of an attractive European “trial market”, thus sav-
ing time and reducing costs of drug development.
CLINICAL EXCELLENCE AND CLINICAL 
TRIAL CENTERS
Italian academic institutions such as Fondazione Poli-
clinico Gemelli in Rome have created their own Clinical 
Trial Center (CTC) to foster excellence in running CTs, 
providing investigators with tools for planning, starting-
up, managing and conducting high quality CTs, allowing 
early exposure of patients to innovative treatments. 
CTCs act as a single interface with industry, guaran-
teeing a homogeneous and efficient process at different 
levels throughout the study process, and can provide 
training for the CT personnel. Funds thus generated 
could primarily be used to finance full-time positions 
of clinical research-dedicated personnel, who will be 
instrumental in running qualitative CTs, ultimately at-
tracting additional clinical research to Europe.
Oncology and pediatrics are examples where such 
cooperation can play a relevant role of benefit to all 
stakeholders. 
Oncology 
Oncology is currently undergoing a transformation 
triggered by new insights in genomics and cellular bi-
ology, characterized by rapid improvement in the un-
derstanding of underlying disease mechanisms and the 
development of targeted drugs. The European Institute 
of Oncology (Istituto Europeo di Oncologia) in Milan, 
an oncology-focused hospital translating basic research 
into an innovative and successful drug discovery pro-
gram, is an example of how investment in basic and 
clinical research through National Health System hos-
pitals can accelerate the discovery of new cancer thera-
pies and improve access to innovation. 
Pediatrics
Drug development programs in adults do not automat-
ically translate to the pediatric setting. Ethical concerns, 
methodological issues, lack of awareness of the need 
for validated pediatric-specific outcome measures, and 
economic reasons are obstacles in performing pediatric 
CTs and increasing the relatively low number of pediatric 
marketing authorizations. Strengthening the application 
of the new EU regulation in the light of specific pediatric 
considerations, including establishing a network of pedi-
atric CTCs, such as the partnership between Bambino 
Gesù Children’s Hospital (Ospedale Pediatrico Bambi-
no Gesù) in Rome and GRiP, would be valuable. 
PUBLIC-PRIVATE PARTNERSHIPS
Available public sector funding is decreasing as medi-
cal needs and scientific complexity increase, and tight 
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collaboration among the private sector, academia and 
government is vital for advancement, fostering the 
translation from basic science to clinical treatment 
through advances in study design and drug develop-
ment [11, 12]. Academicians should guide study design 
and selection of investigator sites, with the industry pro-
viding expertise in study monitoring and reporting. 
Success in drug development derives not only from 
the critical mass of a single company, but from its abil-
ity to enter into an international network of excellence. 
The “Investigator Networks, Site Partnerships and In-
frastructure for Research Excellence” (INSPIRE) pro-
gram, started in 2012 by Pfizer is an innovative model 
for private-public partnerships in R&D that focuses on 
global sites where the most successful clinical research 
is conducted. 
THE CENTRAL ROLE OF THE PATIENT
Traditionally, the prescriber (influenced by the payer/
healthcare system) has been the true counterpart for 
the pharmaceutical companies, with the patient (the 
consumer) accepting what the healthcare professional 
thought best, with little understanding of therapeutic 
options. This era of doctors deciding what is best for a 
patient is coming to an end, as patients are becoming 
more informed and involved in their health. 
Active participation of patient organizations in clini-
cal research is welcome, potentially leading to better 
study designs, higher patient enrollment and retention 
rates, improved credibility of study results and bet-
ter applicability to patients in the real world [13]. We 
encourage further cooperation between patient orga-
nizations, industry, academia and regulatory agencies 
in furthering patient-relevant research to streamline 
study design, improve the economics of research, and 
provide greater generalizability of study results that will 
improve industry chances of having profitable drugs ap-
proved. The new EU Regulation also requires that CT 
data are made accessible to laypersons, an important 
step towards growing awareness and involvement of pa-
tients, and a driver for a better healthcare landscape in 
the EU.
This concept of “Partnerships in medicines develop-
ment = value for all” has been adopted by the European 
Patients’ Academy on Therapeutic Innovation (EU-
PATI), a pan-European project led by the European 
Patients’ Forum and 32 other partners from patient or-
ganizations, universities, non-profit organizations and 
European pharmaceutical companies. It aims to help 
patients become better educated and involved in R&D 
through reliable, objective, comprehensive, lay-friendly 
information and training [14]. 
CONCLUSIONS
We are in broad agreement that consistency of stan-
dards in the development of medical products improves 
the efficiency and transparency of the drug evalua-
tion process, promoting medication quality and pub-
lic health. Implementation of Regulation (EU) No. 
536/2014 should facilitate a more efficient approval 
and execution process for CTs, and we encourage en-
gagement of all stakeholders to carefully implement the 
legislative, administrative and academic adjustments 
required, so that Europe and Italy become a prime lo-
cation for CTs.
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